A phase I clinical trial (protocol for coxsackievirus vaccine in healthy volunteers) evaluating the vaccine candidate has recently started.

The CVB vaccine candidate, PRV-101, was developed for the prevention of acute CVB infection and the potential delay or prevention of type 1 diabetes and celiac disease. Intravacc used its proprietary Vero cell platform to develop current good manufacturing practice (cGMP)-grade viral vaccine production processes for the polyvalent CVB vaccine candidate.

Intravacc receives NIH award to develop enterovirus D68 vaccine
Intravacc has been awarded a $9.4 million contract from the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes...

Intravacc RSV vaccine candidate posts phase I trial results
Intravacc released results of a clinical phase I trial evaluating its live attenuated respiratory syncytial virus (RSV) vaccine candidate.

Intravacc, Celonic to jointly develop COVID-19 vaccine
Vaccine development firm Intravacc and biopharmaceutical contract development and manufacturing organization Celonic are teaming up to develop a COVID-19...

Intravacc, Leiden University explore vaccine quality control without animals
Intravacc has collaborated with the Leiden Academic Center for Drug Research at Leiden University to find alternatives to the use of lab animals in vaccine...

Intravacc, CimCure partner on cancer, COVID-19 vaccines
Intravacc has entered a strategic partnership with CimCure for in-licensing of CimCure's iBoost technology for cancer immunotherapy vaccines and a COVID-19...